dupilumab AD
Selected indexed studies
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. (Lancet, 2019) [PMID:31543428]
- Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. (N Engl J Med, 2022) [PMID:36546624]
- Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. (N Engl J Med, 2021) [PMID:34879449]
_Worker-drafted node — pending editorial review._
Connections
dupilumab AD is a side effect of
Sources
- Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. (2022) pubmed
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. (2019) pubmed
- Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. (2021) pubmed
- Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. (2021) pubmed
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. (2019) pubmed
- Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). (2019) pubmed
- Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. (2024) pubmed
- Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. (2020) pubmed
- Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. (2025) pubmed
- Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. (2020) pubmed